Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801756 | 0.89 | TSHR (0.55) | MAPTHDAC8HDAC2TSHRLMNA | |
| SCHEMBL25802125 | 0.89 | MEN1 (0.46) | TSHRLMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL25802130 | 0.89 | TP53 (0.42) | MAPTTSHRLMNAHPGDALDH1A1 | |
| SCHEMBL25807565 | 0.89 | TP53 (0.42) | MAPTTSHRLMNAHPGDALDH1A1 | |
| SCHEMBL23578358 | 0.86 | TP53 (0.40) | MAPTHDAC8HDAC2TSHRLMNA | |
| SCHEMBL23588102 | 0.85 | SPHK1 (0.48) | MAPTLMNAHPGDFFAR1ALDH1A1 | |
| SCHEMBL23588077 | 0.85 | ACACB (0.52) | MAPTLMNAFFAR1SMN1; SMN2 | |
| SCHEMBL25801975 | 0.85 | TP53 (0.43) | MAPTHDAC8HDAC2TSHRLMNA | |
| SCHEMBL23588271 | 0.84 | SPHK1 (0.53) | — | |
| SCHEMBL25801979 | 0.84 | S1PR4 (0.44) | HDAC8HDAC2TSHRLMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | MAPT 4683/4885HDAC8 2705/4885HDAC2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.